» Articles » PMID: 31137479

Elucidating the Influence of Tumor Presence on the Polymersome Circulation Time in Mice

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2019 May 30
PMID 31137479
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The use of nanoparticles as tumor-targeting agents is steadily increasing, and the influence of nanoparticle characteristics such as size and stealthiness have been established for a large number of nanocarrier systems. However, not much is known about the impact of tumor presence on nanocarrier circulation times. This paper reports on the influence of tumor presence on the in vivo circulation time and biodistribution of polybutadiene-polyethylene oxide (PBd-PEO) polymersomes. For this purpose, polymersomes were loaded with the gamma-emitter In and administered intravenously, followed by timed ex vivo biodistribution. A large reduction in circulation time was observed for tumor-bearing mice, with a circulation half-life of merely 5 min ( = 0.98) vs 117 min ( = 0.95) in healthy mice. To determine whether the rapid polymersome clearance observed in tumor-bearing mice was mediated by macrophages, chlodronate liposomes were administered to both healthy and tumor-bearing mice prior to the intravenous injection of radiolabeled polymersomes to deplete their macrophages. Pretreatment with chlodronate liposomes depleted macrophages in the spleen and liver and restored the circulation time of the polymersomes with no significant difference in circulation time between healthy mice and tumor-bearing mice pretreated with clodronate liposomes (15.2 ± 1.2% ID/g and 13.6 ± 2.7% ID/g, respectively, at 4 h p.i. with = 0.3). This indicates that activation of macrophages due to tumor presence indeed affected polymersome clearance rate. Thus, next to particle design, the presence of a tumor can also greatly impact circulation times and should be taken into account when designing studies to evaluate the distribution of polymersomes.

Citing Articles

Differences in Human Plasma Protein Interactions between Various Polymersomes and Stealth Liposomes as Observed by Fluorescence Correlation Spectroscopy.

Najer A, Rifaie-Graham O, Yeow J, Adrianus C, Chami M, Stevens M Macromol Biosci. 2022; 23(8):e2200424.

PMID: 36447300 PMC: 7615495. DOI: 10.1002/mabi.202200424.


Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability.

Jang H, Jung M, Lee J, Lee J, Lim I, Im H Nanomaterials (Basel). 2022; 12(16).

PMID: 36014656 PMC: 9416411. DOI: 10.3390/nano12162791.


Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics.

Taiarol L, Bigogno C, Sesana S, Kravicz M, Viale F, Pozzi E Cancers (Basel). 2022; 14(12).

PMID: 35740641 PMC: 9220922. DOI: 10.3390/cancers14122978.


Stiffness of targeted layer-by-layer nanoparticles impacts elimination half-life, tumor accumulation, and tumor penetration.

Kong S, Costa D, Jagielska A, Van Vliet K, Hammond P Proc Natl Acad Sci U S A. 2021; 118(42).

PMID: 34649991 PMC: 8594577. DOI: 10.1073/pnas.2104826118.


Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy.

Roobol S, Hartjes T, Slotman J, de Kruijff R, Torrelo G, Abraham T Nanotheranostics. 2020; 4(1):14-25.

PMID: 31911891 PMC: 6940201. DOI: 10.7150/ntno.37080.


References
1.
Wang G, de Kruijff R, Rol A, Thijssen L, Mendes E, Morgenstern A . Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles. Appl Radiat Isot. 2013; 85:45-53. DOI: 10.1016/j.apradiso.2013.12.008. View

2.
Klibanov A, Maruyama K, Torchilin V, Huang L . Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268(1):235-7. DOI: 10.1016/0014-5793(90)81016-h. View

3.
Gabizon A, Papahadjopoulos D . Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988; 85(18):6949-53. PMC: 282096. DOI: 10.1073/pnas.85.18.6949. View

4.
Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P . Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999; 48(7):353-62. PMC: 11037211. DOI: 10.1007/s002620050586. View

5.
Emerich D, Thanos C . Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target. 2007; 15(3):163-83. DOI: 10.1080/10611860701231810. View